Trifluridine / Tipiracil in Combination with Talazoparib for the Treatment of Patients with Locally Advanced or Metastatic Colorectal or Gastroesophageal Cancer
- Histologically or cytologically confirmed CRC or EGC adenocarcinoma that is locally advanced or metastatic
- Has received at least one prior line of therapy with progression or intolerance
- Have measurable disease per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 criteria present
- Have an Eastern Cooperative Oncology Group (ECOG) performance status of 0-1
- Life expectancy >= 3 months by investigator assessment
- Hemoglobin >= 9 g/dL
- Absolute neutrophil count >= 1500/mm^3
- Platelet count >= 100,000/mm^3 without transfusion or growth factor support
- Creatinine < 1.5 upper limit of normal (ULN) or creatinine clearance > 60 mL/min
- Total bilirubin < 1.5 x ULN
- Aspartate aminotransferase (AST)/alanine aminotransferase (ALT) =< 2.5 x ULN or < x 5 ULN in the presence of liver metastasis
- Albumin > 3 g/dL
- Ability to swallow oral medications
- Participants of child-bearing potential must agree to use adequate contraceptive methods (e.g., hormonal or barrier method of birth control; abstinence) prior to study entry. Should a woman become pregnant or suspect she is pregnant while she or her partner is participating in this study, she should inform her treating physician immediately
- Participant or legal representative must understand the investigational nature of this study and sign an Independent Ethics Committee/Institutional Review Board approved written informed consent form prior to receiving any study related procedure
- NOTE: For blood Chemistry labs, Roswell Park clinical blood chemistries are performed on plasma unless otherwise indicated
- Systemic antineoplastic therapy within 2 weeks prior to initiation of FTD/TPI run-in phase (within the past 6 weeks if this treatment is mitomycin C or nitrosourea)
- Radiotherapy within the past 2 weeks excluding palliative radiotherapy to painful bone lesions
- Prior treatment with PARP inhibitor or FTD/TPI
- Any condition that in the investigator’s opinion can limit absorption of FTD/TPI or talazoparib from the gastrointestinal (GI) tract
- Gastrointestinal obstruction (without diversion) or perforation within 4 weeks from initiation of FTD/TPI run-in
- Refractory ascites (requiring weekly or more frequent paracentesis or permanent indwelling peritoneal catheter)
- Untreated central nervous system (CNS) disease. Patients with leptomeningeal disease are ineligible but patients with treated, stable CNS metastasis for at least 4 weeks are allowed to participate
- Significant cardiac disease defined as congestive heart failure stage III or IV (New York Heart Association [NYHA]), acute coronary event, cerebrovascular event, peripheral arterial embolic event, venous thromboembolic event (pulmonary embolism or lower extremity deep vein thrombosis), or ventricular arrhythmia within the past 3 months
- Other malignancy requiring active therapy
- Presence of toxicities from prior therapy of grade 2 or higher
- Active infection requiring antibiotic therapy
- Known human immunodeficiency virus (HIV) or hepatitis B infection or untreated hepatitis C infection. Patients with treated hepatitis C infection and undetectable viral load are allowed to participate
- Any history of myelodysplastic syndrome, acute leukemia, or bone marrow transplant
- Pregnant or nursing female participants
- Unwilling or unable to follow protocol requirements
- Any condition which in the investigator’s opinion deems the participant an unsuitable candidate to receive study drug
I. To determine the safety, maximum tolerated dose (MTD), and recommended phase 2 dose (RP2D) of trifluridine and tipiracil hydrochloride (trifluridine/tipiracil [FTD/TPI]) in combination with talazoparib tosylate (talazoparib) in patients with advanced colorectal (CRC) or gastroesophageal (EGC) adenocarcinoma.
I. To determine the pharmacokinetics (PK) and pharmacodynamic (PD) markers of activity.
II. To evaluate the preliminary antineoplastic efficacy of the combination using overall response rate (ORR), progression free survival (PFS), and overall survival (OS).
I. To determine the role of p53 expression by immunohistochemistry (IHC) and p53 mutations as predictive biomarkers of antineoplastic activity.
II. To determine the significance of somatic and germline deoxyribonucleic acid (DNA) damage repair (DDR) mutations as predictive biomarkers of antineoplastic activity.
III. To determine the dynamics of mutant p53 in circulating tumor (ct)DNA with treatment.
IV. To obtain tissue for future patient-derived xenograft (PDX) studies.
OUTLINE: This is a dose-escalation study of talazoparib.
Patients receive trifluridine/tipiracil orally (PO) twice daily (BID) and talazoparib tosylate PO once daily (QD) on days 1-5. Cycles repeat every 14 days in the absence of disease progression or unacceptable toxicity.
After completion of study treatment, patients are followed up at 30 days and then every 3 months for up to 3 years.
Trial Phase Phase I
Trial Type Treatment
Roswell Park Cancer Institute
- Primary ID I-650120
- Secondary IDs NCI-2020-05678
- Clinicaltrials.gov ID NCT04511039